Literature DB >> 25981178

Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.

Saana Eskelinen1, Eila Sailas, Kaisla Joutsenniemi, Matti Holi, Jaana Suvisaari.   

Abstract

BACKGROUND: Schizophrenia patients are in danger of developing metabolic syndrome (MetS) and its outcomes type 2 diabetes and cardiovascular disease. Antipsychotic treatment and adverse lifestyle increase the burden of metabolic problems in schizophrenia, but little is known about the role of patients' current psychiatric problems and living arrangements in MetS. AIMS: This study aims to evaluate correlations between MetS, severity of psychiatric symptoms, living arrangements, health behaviour and antipsychotic medication in outpatients with schizophrenia spectrum disorders.
METHODS: A general practitioner and psychiatric nurses performed a comprehensive health examination for all consenting patients with schizophrenia spectrum disorders treated in a psychosis outpatient clinic. Examination comprised of an interview, a questionnaire, measurements, laboratory tests and a general clinical examination. Diagnosis of MetS was made according to International Diabetes Federation (IDF) definition. Correlations were calculated and logistic regression analysis performed with SAS.
RESULTS: 276 patients (men n = 152, mean age ± standard deviation = 44.9 ± 12.6 years) participated in the study; 58.7% (n = 162) of them had MetS according to the IDF definition. Clozapine use doubled the risk of MetS (OR = 2.04, 95% CI 1.09-3.82, P = 0.03), whereas self-reported regular physical activity decreased the risk significantly (OR = 0.32, 95% CI 0.18-0.57, P < 0.001). We found no correlations between MetS and living arrangements or current severity of psychiatric symptoms.
CONCLUSIONS: MetS was alarmingly common in our sample. Even moderate physical activity was associated with decreased risk of MetS. Promotion of a physically active lifestyle should be one of the targets in treatment of schizophrenia, especially in patients using clozapine.

Entities:  

Keywords:  Clozapine; Living arrangements; Metabolic syndrome; Physical activity; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25981178     DOI: 10.3109/08039488.2014.983544

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  3 in total

1.  Validation of the Finnish Health Improvement Profile (HIP) with patients with severe mental illness.

Authors:  Camilla Werkkala; Maritta Välimäki; Minna Anttila; Virve Pekurinen; Daniel Bressington
Journal:  BMC Psychiatry       Date:  2020-03-11       Impact factor: 3.630

2.  Patterns of primary care among persons with schizophrenia: the role of patients, general practitioners and centre factors.

Authors:  Mª Carmen Castillejos Anguiano; Carlos Martín Pérez; Antonio Bordallo Aragón; Jesus Sepúlveda Muñoz; Berta Moreno Küstner
Journal:  Int J Ment Health Syst       Date:  2020-11-10

3.  Gait Alterations in the Prediction of Metabolic Syndrome in Patients With Schizophrenia: A Pilot Study With PODOSmart ® Insoles.

Authors:  Dimitris Efthymiou; Dimitrios X Zekakos; Evangelia Papatriantafyllou; Efthimis Ziagkas; Alexandros N Petrelis; Emilia Vassilopoulou
Journal:  Front Psychiatry       Date:  2022-01-27       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.